Joshua Zeidner MD
@LeukDocJZ
Followers
2K
Following
6K
Media
211
Statuses
2K
Associate Prof of Med @UNC_Lineberger | Oncologist | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | NYG & Tar Heels|Views my own
Chapel Hill, NC
Joined May 2019
Looking forward to this fantastic meeting next week with an all star lineup 👇.
🗓 Next Week: We're just days away from the 4th Annual AML-ALL US Focus Meeting 2025, taking place July 10–12 at the Marina del Rey Marriott, CA. A huge thank you to our co-chairs for curating an outstanding agenda and world-class faculty:.▪️ @Daver_Leukemia – MD Anderson Cancer
0
2
11
Fascinating results and data! Great work @TaylorJ_MD and team!.
Our new paper is out @Nature_NPJ Precision Oncology! .With @JustinWattsMD and colleagues @SylvesterCancer we report on the first patient functionally cured by single-agent IDH1 inhibition with Olutasidenib @RigelPharma for r/r #AML @NaturePortfolio 🧵.
0
0
4
This 👇. Never underestimate the power of hope for patients with cancer!.
👏 I saw an interesting anecdote and just looked up the reference. Literally before I was born, an oncologist very succinctly and elegantly summarized how we offer hope to our patients living with cancer. these words are still true today!.
1
7
28
Could not have done the study without Alice’s & @beatalleukemia Beat AML leadership, support and advocacy @OSUHematology 🙏.
📢New hope for AML patients: A study co-authored by @OSUCCC_James Alice Mims & @beatalleukemia shows azacitidine+venetoclax+revumenib achieved an 88% response rate in newly diagnosed NPM1-mutated or KMT2A-rearranged AML @JCO_ASCO. Incredible work!🧬🩸.🔗
0
2
12
A combination therapy that adds a new drug to the current care for newly diagnosed acute myeloid leukemia showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger and 11 other sites. -.Read the full study here:
2
5
17
Proud of @DPetersMD for completing his Heme/Onc fellowship and Chief year @UNC_Lineberger @UNCDeptMedicine. Beyond excited to see all that you will accomplish at Georgia Cancer Center! Of course, had to celebrate with lunch at Merritt’s (IYKYK)!
3
3
25
Very disappointing results from VERONA Study. We need to reevaluate our study designs and endpoints in MDS.
With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1
0
5
17
RT @dominicandoc2: Huge congratulations to @LeukDocJZ on a stellar @EHA_Hematology presentation + first-author @JCO_ASCO publication!. The….
0
7
0
congrats to @DrWendyStock & @myeloidmalig who are co-authors on the @JCO_ASCO publication focusing on the BEAT AML cohort of patients treated with Aza + Ven + Revumenib!.
0
2
11
It was an honor to present the results of the Aza/Ven/Revumenib BEAT AML study @EHA_Hematology & published @JCO_ASCO. Beyond excited that these results have led to the design and development of a RP3 trial of Aza/Ven + Revumenib/placebo in newly Dx AML w/ NPM1m. @UNC_Lineberger
7
8
64
RT @calliecoombsmd: @LeukDocJZ presenting on the Beat AML aza/ven/revumenib trial in pts with NPM1 mutated / KMT2A rearranged AML - high OR….
0
3
0
RT @JCO_ASCO: ‼️ #EHA2025 #JCO simultaneous publication by @LeukDocJZ et al: . Azacitidine, Venetoclax and Revumenib for Newly Diagnosed NP….
0
7
0
Impressive results of 7+3 + Ziftomenib in newly diagnosed AML patients with NPM1m or KMT2Ar presented by Harry Erba. We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly Dx AML w/ NPM1m or KMT2Ar. @EHA_Hematology #EHA25
1
15
50
Looking forward to kicking off the oral abstract session in AML with Gail Roboz presenting data on oral Decitabine-Cedazuridine and Venetoclax in newly Dx older AML pts @EHA_Hematology #EHA25
0
3
23
Thanks to @binaytara for hosting the first annual North Carolina Hematologic Malignancies Symposium in Durham chaired by Debbie Stephens @UNC_Lineberger. It was an honor to speak with all star lineup of speakers.
0
4
31
Amazing work, Patrick! Congratulations to you and all authors. I remember when you first developed this concept in fellowship @hopkinskimmel. What an incredible journey!.
~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! #LCSM 1/
0
1
4
Quite the all star AML crew!.
Thank you to @Daver_Leukemia, @jaltmanmd, and Dr. Alice Mims for leading an engaging @PeerView x @HealthTree #AML symposium at #ASCO25! If you missed the live session, stay tuned for the replay.
0
2
4
Hot off the press! Our GEN-PHEN-VEN study led by @CLachowiez showing the importance of phenotype for risk class. of AML Tx w/ Aza/Ven. Monocytic diff. associated w/ worse outcomes and should be part of our risk class. Glad to be part of this impactful analysis @UNC_Lineberger.
Our new publication is out today in the OnlineFirst section of @BCD_AACR! . We explored correlations between monocytic AML, genetics, and survival by leveraging a large international clinical cohort of patients with AML treated with HMA+VEN.
0
7
25
Congrats @zucenka and the whole Augment-101 team! Finally R/R NPM1m data with Revumenib hot off the press 👇.
Hot off the press: AUGMENT-101 trial results of Revumenib in R/R NPM1m AML. Congratulations to everyone who contributed to this important therapeutical advancement!. A huge privillege to have our team involved and to be able to help our AML patients.
0
2
10